Cargando…
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial
IMPORTANCE: Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC). Patients who have undergone gastrectomy constitute a significant proportion of patients with mGC/GEJC. OBJECTIVE: To...
Autores principales: | Ilson, David H., Tabernero, Josep, Prokharau, Aliaksandr, Arkenau, Hendrik-Tobias, Ghidini, Michele, Fujitani, Kazumasa, Van Cutsem, Eric, Thuss-Patience, Peter, Beretta, Giordano D., Mansoor, Wasat, Zhavrid, Edvard, Alsina, Maria, George, Ben, Catenacci, Daniel, McGuigan, Sandra, Makris, Lukas, Doi, Toshihiko, Shitara, Kohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802061/ https://www.ncbi.nlm.nih.gov/pubmed/31600365 http://dx.doi.org/10.1001/jamaoncol.2019.3531 |
Ejemplares similares
-
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS
por: Tabernero, Josep, et al.
Publicado: (2020) -
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
por: Mansoor, Wasat, et al.
Publicado: (2021) -
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
por: Tabernero, J., et al.
Publicado: (2021) -
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
por: Van Cutsem, E., et al.
Publicado: (2022) -
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
por: Shitara, Kohei, et al.
Publicado: (2022)